Recent care and future directions in the clinical management of chronic obstructive pulmonary disease

Chronic obstructive pulmonary disease (COPD) develops through the interaction of long-term environmental injury and biological susceptibility, which activates self-reinforcing networks of chronic inflammation, oxidative and mitochondrial stress, protease–antiprotease imbalance, cellular senescence, impaired tissue repair, and epigenetic/transcriptional reprogramming. By the time airflow limitation becomes clinically apparent, substantial alveolar and small-airway damage has often already occurred. Current pharmacological therapies improve symptoms, reduce exacerbation burden, and partially modulate inflammatory activity; however, they do not restore destroyed lung architecture or reverse the underlying degenerative process. The strongest pharmacological evidence for improved survival in COPD is for inhaled triple therapy (ICS/LAMA/LABA. The few non-pharmacologic interventions associated with survival benefit act in specific clinical contexts: long-term oxygen therapy corrects severe resting hypoxaemia, non-invasive ventilation ameliorates chronic hypercapnic ventilatory failure, and lung transplantation replaces end-stage lung function. None of these interventions restore damaged lung architecture. This highlights the central challenge in COPD: established structural destruction is difficult to reverse, while the biological mechanisms that drive degeneration and failed repair remain incompletely targetable. Until effective disease-modifying and regenerative therapies become available, prevention remains the most powerful strategy, including smoking cessation, reduction of occupational and environmental exposures, and early limitation of factors that accelerate disease progression. Future therapeutic progress will depend on shifting from downstream symptom control toward interventions capable of preserving lung structure, restoring repair capacity, and interrupting the self-sustaining cycle of injury, inflammation, and maladaptive tissue remodeling. Whether emerging approaches can achieve this remains uncertain, but major improvements in long-term outcomes are unlikely without addressing the mechanisms responsible for ongoing lung destruction and impaired repair.

Authors

Institutions

Publication Details

Journal
Frontiers in Medicine
Published
2026-11-18
DOI
https://doi.org/10.3389/fmed.2026.1952056
Primary Topic
Chronic Obstructive Pulmonary Disease (COPD) Research
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Recent care and future directions in the clinical management of chronic obstructive pulmonary disease

Gábor J. Szebeni, Szilvia Török, Klára Szalontai, Erzsébet Schlegl et al.
1 links
Frontiers in Medicine
Chronic Obstructive Pulmonary Disease (COPD) Research
article

Recent care and future directions in the clinical management of chronic obstructive pulmonary disease

Gábor J. Szebeni, Szilvia Török, Klára Szalontai, Erzsébet Schlegl, Júlia Masa, Péter Simon
article en

Abstract

Chronic obstructive pulmonary disease (COPD) develops through the interaction of long-term environmental injury and biological susceptibility, which activates self-reinforcing networks of chronic inflammation, oxidative and mitochondrial stress, protease–antiprotease imbalance, cellular senescence, impaired tissue repair, and epigenetic/transcriptional reprogramming. By the time airflow limitation becomes clinically apparent, substantial alveolar and small-airway damage has often already occurred. Current pharmacological therapies improve symptoms, reduce exacerbation burden, and partially modulate inflammatory activity; however, they do not restore destroyed lung architecture or reverse the underlying degenerative process. The strongest pharmacological evidence for improved survival in COPD is for inhaled triple therapy (ICS/LAMA/LABA. The few non-pharmacologic interventions associated with survival benefit act in specific clinical contexts: long-term oxygen therapy corrects severe resting hypoxaemia, non-invasive ventilation ameliorates chronic hypercapnic ventilatory failure, and lung transplantation replaces end-stage lung function. None of these interventions restore damaged lung architecture. This highlights the central challenge in COPD: established structural destruction is difficult to reverse, while the biological mechanisms that drive degeneration and failed repair remain incompletely targetable. Until effective disease-modifying and regenerative therapies become available, prevention remains the most powerful strategy, including smoking cessation, reduction of occupational and environmental exposures, and early limitation of factors that accelerate disease progression. Future therapeutic progress will depend on shifting from downstream symptom control toward interventions capable of preserving lung structure, restoring repair capacity, and interrupting the self-sustaining cycle of injury, inflammation, and maladaptive tissue remodeling. Whether emerging approaches can achieve this remains uncertain, but major improvements in long-term outcomes are unlikely without addressing the mechanisms responsible for ongoing lung destruction and impaired repair.

Frontiers in MedicineVol. 13
University of Szeged (HU), HUN-REN Szegedi Biológiai Kutatóközpont (HU), Országos Korányi Tbc és Pulmonológiai Intézet (HU), Hungarian Research Network (HU)
Nemzeti Kutatási Fejlesztési és Innovációs Hivatal
Good health and well-being
Chronic Obstructive Pulmonary Disease (COPD) Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon